Spero Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDSpero Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 36), showing significant lag compared to the market leaders. Earnings growth of 48% provides fundamental context to the price action. Investors should exercise caution due to high volatility (60% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.54 | -10.90% | BELOW |
| 50 SMA | $2.62 | -13.58% | BELOW |
| 100 SMA | $2.52 | -10.30% | BELOW |
| 150 SMA | $2.46 | -8.23% | BELOW |
| 200 SMA | $2.40 | -5.93% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SPRO in an uptrend right now?
SPRO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is SPRO overbought or oversold?
SPRO's RSI (14) is 43. The stock is in neutral territory, neither overbought nor oversold.
Is SPRO outperforming the market?
SPRO has a Relative Strength (RS) Rating of 36 out of 99. SPRO is currently lagging the broader market.
Where is SPRO in its 52-week range?
SPRO is trading at $2.26, which is 70% of its 52-week high ($3.22) and 32% above its 52-week low ($1.80).
How volatile is SPRO?
SPRO has a Beta of 1.53 and 52-week volatility of 60%. It's more volatile than the S&P 500 - expect bigger swings.